Social media

The volume of life sciences research is growing fast - making it harder than ever to find reliable insights. Our new whitepaper shows you how to use systematic literature reviews (SLRs) to generate high-quality evidence ...

Agencies like the FDA and EMA are more receptive to submissions integrating evidence across indications, lowering barriers for label expansion. But what commercialisation strategies are most successful following regul...

The therapeutic landscape for obesity is changing rapidly. Endpoints focused only on weight loss are no longer enough. Regulators now expect measures that capture the entire patient experience. Join ICON experts on Oct...

Biomarkers aren’t just supporting drug development, they’re driving it. This expert-led report produced in conjunction with Drug Target Review explores how biomarker science is advancing trial design, accelerating clinic...

Customised collaboration -- Discover how we helped sponsors transition to blended models, drive efficiency and create impactful outcomes. Learn more across a range of real-world case studies. Explore the outcomes here: ...

At ICON we believe exceptional careers are built through purpose, leadership and local impact. In our latest blog, we shine a light on Karen Hahn’s leadership as Senior Director of Project Operations & Site Head in Mexic...

ICON is pleased to join industry leaders #DPHARM2025, taking place 16 - 17 September at the Loews Philadelphia Hotel. Visit us at booth #305 to connect with our experts and learn how ICON’s clinical, consulting, and com...

Antibody-Drug Conjugates (ADCs) combine potent cytotoxins with selective antibodies for targeted cancer therapy—but their complexity presents major challenges in pharmacokinetics (PK) and bioanalysis. In our latest artic...

In the fast-paced world of pharma, making informed decisions starts with understanding the evidence. But with research output growing exponentially, how do you keep up? Our new whitepaper, “Demystifying the SLR: ‘S’ Sta...

Antibody-drug conjugates (ADCs) represent a growing class of targeted therapies, but their pharmacokinetic assessment presents unique challenges due to structural complexity, multiple analytes, and the need for diverse a...

The next in our UK regulatory environment blog series is out now. In this instalment we discuss the opportunity for interactions with both the MHRA and the National Institute for Health and Care Excellence (NICE). These ...

When commercialising a multi-indication drug, a narrow first launch strategy targets high-value populations for premium pricing but may slow accumulation of real world evidence. Understand these trade-offs in our arti...